Actinium Pharmaceuticals, Inc. (ATNM)
USD 1.16
(-4.92%)
USD 1.16
(-4.92%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.11 Million USD | -18.13% |
| 2022 | 2.58 Million USD | 732.58% |
| 2021 | 310 Thousand USD | -57.99% |
| 2020 | 738 Thousand USD | -48.32% |
| 2019 | 1.42 Million USD | 443.85% |
| 2018 | 262.59 Thousand USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | -100.0% |
| 2015 | 265.69 Thousand USD | -6.3% |
| 2014 | 283.55 Thousand USD | 79.66% |
| 2013 | 157.82 Thousand USD | 12.73% |
| 2012 | 140 Thousand USD | 16.67% |
| 2011 | 120 Thousand USD | 100.0% |
| 2010 | 60 Thousand USD | -12.43% |
| 2009 | 68.51 Thousand USD | 37.5% |
| 2008 | 49.82 Thousand USD | 38.57% |
| 2007 | 35.95 Thousand USD | 147.99% |
| 2006 | 14.5 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.98 Million USD | -6.2% |
| 2024 Q2 | 1.84 Million USD | -6.71% |
| 2023 Q1 | 2.46 Million USD | -4.69% |
| 2023 FY | 2.11 Million USD | -18.13% |
| 2023 Q2 | 2.33 Million USD | -5.0% |
| 2023 Q3 | 2.21 Million USD | -5.39% |
| 2023 Q4 | 2.11 Million USD | -4.43% |
| 2022 Q3 | 2.6 Million USD | -1.77% |
| 2022 FY | 2.58 Million USD | 732.58% |
| 2022 Q2 | 2.64 Million USD | 1244.16% |
| 2022 Q4 | 2.58 Million USD | -0.77% |
| 2022 Q1 | 197 Thousand USD | -36.45% |
| 2021 Q4 | 310 Thousand USD | -26.37% |
| 2021 Q3 | 421 Thousand USD | -20.42% |
| 2021 Q2 | 529 Thousand USD | -16.56% |
| 2021 Q1 | 634 Thousand USD | -14.09% |
| 2021 FY | 310 Thousand USD | -57.99% |
| 2020 FY | 738 Thousand USD | -48.32% |
| 2020 Q1 | 1.3 Million USD | -8.76% |
| 2020 Q3 | 877 Thousand USD | -19.69% |
| 2020 Q4 | 738 Thousand USD | -15.85% |
| 2020 Q2 | 1.09 Million USD | -16.19% |
| 2019 Q2 | 1.41 Million USD | -9.95% |
| 2019 Q3 | 1.25 Million USD | -11.75% |
| 2019 Q4 | 1.42 Million USD | 14.13% |
| 2019 FY | 1.42 Million USD | 443.85% |
| 2019 Q1 | 1.57 Million USD | 499.58% |
| 2018 FY | 262.59 Thousand USD | 0.0% |
| 2018 Q4 | 262.59 Thousand USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 Q1 | 178.11 Thousand USD | -32.96% |
| 2016 Q3 | - USD | -100.0% |
| 2016 Q2 | 89.56 Thousand USD | -49.71% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | -100.0% |
| 2015 Q4 | 265.69 Thousand USD | 0.0% |
| 2015 Q2 | 92.26 Thousand USD | -51.38% |
| 2015 Q1 | 189.75 Thousand USD | -33.08% |
| 2015 Q3 | - USD | -100.0% |
| 2015 FY | 265.69 Thousand USD | -6.3% |
| 2014 Q2 | 54.97 Thousand USD | -41.82% |
| 2014 Q4 | 283.55 Thousand USD | 0.0% |
| 2014 Q3 | - USD | -100.0% |
| 2014 FY | 283.55 Thousand USD | 79.66% |
| 2014 Q1 | 94.48 Thousand USD | -40.14% |
| 2013 FY | 157.82 Thousand USD | 12.73% |
| 2013 Q4 | 157.82 Thousand USD | 0.0% |
| 2013 Q3 | - USD | -100.0% |
| 2013 Q2 | 36.95 Thousand USD | -50.51% |
| 2013 Q1 | 74.66 Thousand USD | -46.67% |
| 2012 FY | 140 Thousand USD | 16.67% |
| 2012 Q3 | 72.85 Thousand USD | 2.24% |
| 2012 Q2 | 71.26 Thousand USD | 11.04% |
| 2012 Q1 | 64.17 Thousand USD | 10.32% |
| 2012 Q4 | 140 Thousand USD | 92.16% |
| 2011 FY | 120 Thousand USD | 100.0% |
| 2011 Q4 | 58.16 Thousand USD | 8.21% |
| 2011 Q3 | 53.75 Thousand USD | 0.0% |
| 2011 Q2 | 53.75 Thousand USD | -14.44% |
| 2011 Q1 | 62.82 Thousand USD | 0.0% |
| 2010 Q1 | 73.01 Thousand USD | 6.57% |
| 2010 FY | 60 Thousand USD | -12.43% |
| 2010 Q2 | 75.36 Thousand USD | 3.22% |
| 2010 Q3 | 53.63 Thousand USD | -28.84% |
| 2010 Q4 | - USD | -100.0% |
| 2009 Q1 | 60.05 Thousand USD | 20.52% |
| 2009 Q4 | 68.51 Thousand USD | 4.78% |
| 2009 Q3 | 65.38 Thousand USD | 8.65% |
| 2009 Q2 | 60.18 Thousand USD | 0.22% |
| 2009 FY | 68.51 Thousand USD | 37.5% |
| 2008 Q4 | 49.82 Thousand USD | 6.41% |
| 2008 Q2 | 41.99 Thousand USD | 7.69% |
| 2008 Q3 | 46.82 Thousand USD | 11.5% |
| 2008 FY | 49.82 Thousand USD | 38.57% |
| 2008 Q1 | 38.99 Thousand USD | 8.45% |
| 2007 Q3 | 31.45 Thousand USD | 50.95% |
| 2007 FY | 35.95 Thousand USD | 147.99% |
| 2007 Q2 | 20.84 Thousand USD | 43.72% |
| 2007 Q1 | 14.5 Thousand USD | 0.0% |
| 2007 Q4 | 35.95 Thousand USD | 14.3% |
| 2006 Q4 | 14.5 Thousand USD | 0.0% |
| 2006 FY | 14.5 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 495 Thousand USD | -326.869% |
| Ampio Pharmaceuticals, Inc. | 274 Thousand USD | -671.168% |
| Armata Pharmaceuticals, Inc. | 120.37 Million USD | 98.245% |
| Azitra, Inc. | 885.94 Thousand USD | -138.502% |
| Can-Fite BioPharma Ltd. | 39.99 Thousand USD | -5182.632% |
| Chromocell Therapeutics Corporation | 1.26 Million USD | -66.55% |
| Calidi Biotherapeutics, Inc. | 7.23 Million USD | 70.799% |
| CEL-SCI Corporation | 13.57 Million USD | 84.431% |
| iBio, Inc. | 4.46 Million USD | 52.623% |
| Lineage Cell Therapeutics, Inc. | 2.95 Million USD | 28.421% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 3.55 Million USD | 40.579% |
| Navidea Biopharmaceuticals, Inc. | 2.43 Million USD | 13.199% |
| NovaBay Pharmaceuticals, Inc. | 2.74 Million USD | 22.883% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | 312.7 Thousand USD | -575.721% |
| BiomX Inc. | 15.09 Million USD | 85.999% |
| BiomX Inc. | 15.09 Million USD | 85.999% |
| Protalix BioTherapeutics, Inc. | 26.28 Million USD | 91.96% |
| Palatin Technologies, Inc. | 590.33 Thousand USD | -257.931% |
| Scorpius Holdings, Inc. | 14.04 Million USD | 84.952% |